<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13381">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02042807</url>
  </required_header>
  <id_info>
    <org_study_id>MCS-8-II-TWN</org_study_id>
    <nct_id>NCT02042807</nct_id>
  </id_info>
  <brief_title>To Evaluate the Effect of MCS® in Prostate Cancer Prevention</brief_title>
  <acronym>MCS-8</acronym>
  <official_title>A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS® in Prostate Cancer Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Ever Bio-Tech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Health Ever Bio-Tech Co., Ltd.</source>
  <oversight_info>
    <authority>Taiwan: Taiwan Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of MCS® compared with placebo in reducing the risk of
      biopsy-detectable prostate cancer in high-risk subjects after 104 weeks (24 months) of
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Cumulative biopsy-detectable prostate cancer rate</measure>
    <time_frame>Week 104 (Month 24)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">702</enrollment>
  <condition>1. High-risk Subjects of Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCS® 15 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MCS® 15 mg/day, soft capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCS® 30 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MCS® 30 mg/day, soft capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCS®</intervention_name>
    <arm_group_label>MCS® 15 mg/day</arm_group_label>
    <arm_group_label>MCS® 30 mg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1) Four groups of high-risk subjects of prostate cancer. (2) Male subject with age
             from 50 to 75 years old. (3) No active urinary tract infection (UTI) or bacterial
             prostatitis. (4) Subject is able to understand and willing to comply with the study
             procedures and has signed the informed consent form (ICF).

        Exclusion Criteria:

          -  (1) Subjects' elevated PSA is deemed by the investigators solely to inflammation or
             infection of the prostate.

             (2) Subjects who are or will be taking long-term hormonal agents that may affect the
             normal physiology of sex hormone function.

             (3) Subjects with a PSA &gt; 10.0 ng/ml. I (4) Subjects with a history of prostate
             cancer. (5) Subjects are currently taking or planning to take oral bile acid
             sequestrants.

             (6) Subjects have celiac disease, Crohn's disease, partly removal of the intestinal
             tract (surgically), or any malabsorption conditions.

             (7) Subject participated in another investigational agent study in the past 30 days
             or is planning to do so during the study period.

             (8) Subjects are considered ineligible for the study as judged by the investigator.

             (9) Other malignancies except non-melanoma skin cancer.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fu-Feng Kuo</last_name>
    <phone>+886 2 25788621</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Urology, National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yeong-Shiau Pu</last_name>
      <phone>+886 2 23123456</phone>
    </contact>
    <investigator>
      <last_name>Yeong-Shiau Pu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 21, 2014</lastchanged_date>
  <firstreceived_date>January 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
